Natixis Bei Gene, Ltd. Transaction History

Natixis

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$221.31 - $316.61 $12.9 Million - $18.4 Million	-58,173 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$189.18 - $286.44 $11 Million - $16.7 Million	58,173 New	58,173 $16.7 Million
Q2 2020 Aug 13, 2020	SELL	$123.9 - $195.41 $4.27 Million - $6.73 Million	-34,437 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$121.84 - $173.19 $4.2 Million - $5.96 Million	34,437 New	34,437 $4.24 Million
Q2 2019 Aug 13, 2019	SELL	$113.99 - $146.86 $2.86 Million - $3.68 Million	-25,077 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$122.82 - $151.83 $7,737 - $9,565	-63 Reduced 0.25%	25,077 $3.17 Million
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $2.69 Million - $4.4 Million	25,140 New	25,140 $3.53 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.